CN1194156A - Life gate adaptagen - Google Patents
Life gate adaptagen Download PDFInfo
- Publication number
- CN1194156A CN1194156A CN98101352A CN98101352A CN1194156A CN 1194156 A CN1194156 A CN 1194156A CN 98101352 A CN98101352 A CN 98101352A CN 98101352 A CN98101352 A CN 98101352A CN 1194156 A CN1194156 A CN 1194156A
- Authority
- CN
- China
- Prior art keywords
- radix
- adaptagen
- melatonin
- chinese medicine
- life gate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Life gate adaptagen, one Chinese medicine composite for curing cancer and cardio- and cerebral- angiopathy, consists of schisandra 25-35%, later silkworm excrement 10-15%, Spica Prunellae 5-10%, Rhizoma Corydalis Decumbentis 5-12%, rhodiola root 5-10%, Radix Acanthopanacis Senticosi 3-8%, Radix Bupleuri 2-5%, hexabutylsaccharide 8-12% and melatonin 1-2.5%. The present invention has deternined cure effect, can regulate body's function and strengthen immunity while cure disease. It has effective rate of 90%.
Description
The present invention relates to a kind of Chinese medicine composition for the treatment of cancer and cardiovascular and cerebrovascular disease.
At present the treatment for cancer method has two big classes, and a class is a traditional remedies, and as operation, radiotherapy, chemotherapy, these class methods are only paid attention to " eliminating evil ", and have ignored integral body, and is strong to the tissue of tumor and cell removing and lethality, but damaging quite big to body.In addition tumour patient mostly in finding to be all, late period, the whole body resistance reduces, thus not too suitable to traditional method, also can quicken to worsen, promote death sometimes.Another kind of is Chinese medicine, and this class methods relative adaptation disease is wide, also very pays attention to integral body, but because the shortage Systems Theory instructs, does not have the property of commander medicine, so general effect is relatively poor.
The purpose of this invention is to provide a kind of determined curative effect, can treat to be beneficial to again simultaneously and regulate the whole treatment cancer and the Chinese medicine composition-life gate adaptagen of cardiovascular and cerebrovascular disease.
The object of the present invention is achieved like this: a kind of Chinese medicine composition that is used for the treatment of cancer and cardiovascular and cerebrovascular disease--life gate adaptagen, it is characterized in that forming: Radix Schisandrae Bicoloris 25--35% by following component and part by weight, late Bombyx mori L. 10--15%, Spica Prunellae 5--10%, Rhizoma Corydalis Decumbentis 5--12%, Radix Rhodiolae 5--10%, Radix Et Caulis Acanthopanacis Senticosi 3--8%, Radix Bupleuri 2--5%, chitosan 8--12%, melatonin 1--2.5%.
Purpose of the present invention can also following manner realize: the part by weight of each component is: Radix Schisandrae Bicoloris 33%, late Bombyx mori L. 13%, Spica Prunellae 10%, Rhizoma Corydalis Decumbentis 10%, Radix Rhodiolae 10%, Radix Et Caulis Acanthopanacis Senticosi 6%, Radix Bupleuri 3%, chitosan 10%, melatonin 2.5%.
The present invention has following advantage and good effect: determined curative effect, and not only be used for the treatment of but also can adjust the whole body function simultaneously, enhance immunity, through clinical anticancer patient 30 example statistics, total effective rate is 90%.Its mechanism of action is, Radix Schisandrae Bicoloris, Radix Rhodiolae, Radix Et Caulis Acanthopanacis Senticosi, chitosan belong to adaptogen class material together, the collaborative merit of tool not only between four, and four component accounts for 2/3rds of total component, guaranteed that our adaptogen occupies an leading position, its major function is an enhance immunity, conditioning whole body, antitonic, radioprotective, antibiotic, anticancer, antitoxin, fatigue-resisting function; Health is had concurrently protective effect and stimulates the function of repairing, thereby can help each physiological function of health to reach optimum state.Evening, Bombyx mori L. had a surname to lead turbid merit clearly; The little suffering of Spica Prunellae and sweet among the eliminating stagnation, has the merit with positive yin nourishing concurrently; Summer incompetent qi and blood circulation promotion, the meridian dredging, the pain that relieves the pain, the three share, and can not only proofread and correct the property of the astringent therapy of Radix Schisandrae Bicoloris, and exchanges that to reach state of internal organs mechanism of qi also essential.Radix Bupleuri, but few with sending up the lucid YANG, because of falling of vigour, must this in liter, though so survival dose is few, but compatibility key.Melatonin is a pinus secretions, the significant anti-aging effects of tool, and every day, 2mg can obviously improve sleep, and this is the important substance basis that adapts to the integrally-regulated effect of originality.
Elaborate below in conjunction with embodiment:
One, proportioning components: in per 15 No. 2 capsule finished product net content 3g, wherein each component content is: Radix Schisandrae Bicoloris 1g, late Bombyx mori L. 0.4g, Spica Prunellae 0.3g, Rhizoma Corydalis Decumbentis 0.3g, Radix Rhodiolae 0.3g, Radix Et Caulis Acanthopanacis Senticosi 0.2g, Radix Bupleuri 0.1g, chitosan (deacetylation is more than 85%) 0.325g, melatonin 0.075g.
Two, preparation method: other Chinese herbal medicine except that chitosan, melatonin are mixed, pulverize, cross 100 mesh sieves, add chitosan again, melatonin fine powder, the capsule of packing into No. 2 after fully mixing, every net content 200mg.
Three, indication: be applicable to cancer, particularly in, terminal cancer and cardiovascular and cerebrovascular disease.Also can be used for hepatopathy, diabetes, retinopathy and health of older persons.
Four, usage and dosage: oral, three times on the one, each 1g.
Five, clinical anticancer statistical effect: use the present invention and treat late tumor 30 examples, wherein: esophageal carcinoma 5 examples, gastric cancer 5 examples, pulmonary carcinoma 8 examples, hepatocarcinoma 4 examples, adnexal carcinoma 2 examples, mammary cancer 1 example, osteocarcinoma 1 example, other 4 example.All have the 1--3 place to shift before all patient, 80% patient carried out 1--2 kind traditional method and failed to respond to any medical treatment, and had the above Chinese medicine of 1 class and other method to fail to respond to any medical treatment.Through using life gate adaptagen treatment three above statistical result of week of the present invention as follows: clinical cure 4 examples, 8 examples that are clearly better, effective 15 examples, invalid 3 examples, total effective rate 90%.The shortest person of doing well,improving seven days is generally more than 20 days.Tumor auxiliary examination (X-ray, B ultrasonic, CT, MRI) can check out that the person of dwindling is greatly about more than 1 month; Disappear or disappear generally three of medications more than the first quarter moon substantially.Through clinical practice, the present invention also has significant curative effect for the treatment cardiovascular and cerebrovascular disease in addition.
Claims (2)
1, a kind of Chinese medicine composition that is used for the treatment of cancer and cardiovascular and cerebrovascular disease--life gate adaptagen, it is characterized in that forming: Radix Schisandrae Bicoloris 25--35% by following component and part by weight, late Bombyx mori L. 10--15%, Spica Prunellae 5--10%, Rhizoma Corydalis Decumbentis 5--12%, Radix Rhodiolae 5--10%, Radix Et Caulis Acanthopanacis Senticosi 3--8%, Radix Bupleuri 2--5%, chitosan 8--12%, melatonin 1--2.5%.
2, Chinese medicine composition--the life gate adaptagen of treatment cancer according to claim 1 and cardiovascular and cerebrovascular disease, the part by weight that it is characterized in that each component is: Radix Schisandrae Bicoloris 33%, late Bombyx mori L. 13%, Spica Prunellae 10%, Rhizoma Corydalis Decumbentis 10%, Radix Rhodiolae 10%, Radix Et Caulis Acanthopanacis Senticosi 6%, Radix Bupleuri 3%, chitosan 10%, melatonin 2.5%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98101352A CN1194156A (en) | 1998-04-10 | 1998-04-10 | Life gate adaptagen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98101352A CN1194156A (en) | 1998-04-10 | 1998-04-10 | Life gate adaptagen |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1194156A true CN1194156A (en) | 1998-09-30 |
Family
ID=5216638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98101352A Pending CN1194156A (en) | 1998-04-10 | 1998-04-10 | Life gate adaptagen |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1194156A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117566A3 (en) * | 2005-05-03 | 2007-06-14 | Ultra Biotech Ltd | Botanical anticancer formulations |
CN104173585A (en) * | 2014-08-29 | 2014-12-03 | 北京世纪合辉医药科技股份有限公司 | Adaptogen preparation containing rhodiola rosea and preparation method thereof |
-
1998
- 1998-04-10 CN CN98101352A patent/CN1194156A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006117566A3 (en) * | 2005-05-03 | 2007-06-14 | Ultra Biotech Ltd | Botanical anticancer formulations |
CN104173585A (en) * | 2014-08-29 | 2014-12-03 | 北京世纪合辉医药科技股份有限公司 | Adaptogen preparation containing rhodiola rosea and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1679864A (en) | Chinese medicine preparation for treating bronchitis | |
CN101485834B (en) | Chinese medicine for treating diabetes | |
CN115463200B (en) | Traditional Chinese medicine composition and patch for treating adenoid hypertrophy and preparation method thereof | |
CN106963921A (en) | It is a kind of to treat external medicine composition of the proliferation of mammary gland and preparation method thereof | |
CN101829248B (en) | Traditional Chinese medicine for treating goiter | |
CN1194156A (en) | Life gate adaptagen | |
CN1178679C (en) | Medicine for treating asthma, acute and chronic bronchitis and emphysema | |
CN101979035A (en) | Medicament for treating gynecological abnormal leucorrhea | |
CN102228624A (en) | Medicament for treating pharyngitis and preparation method thereof | |
CN101837111A (en) | Medicament for curing proliferation of mammary glands and preparation method thereof | |
CN1056517C (en) | Anal fistula eliminating medicine | |
CN102293992B (en) | Traditional Chinese medicine for treating radiation pneumonitis | |
CN1174769C (en) | Chinese-medicinal bag tea for treating chronic pharyngitis and vocal fold disease and its preparing process | |
CN110496181B (en) | Chinese medicinal capsule and its preparation method | |
CN101618102B (en) | Chinese traditional medicine preparation for treating breast diseases and preparing method thereof | |
CN1263493C (en) | Medicine for treating chronic bronchitis and asthma | |
CN107617039B (en) | Traditional Chinese medicine composition for treating lumbar vertebrae hyperosteogeny and preparation thereof | |
CN105106468A (en) | Antineoplastic traditional Chinese medicine composition for medical oncology | |
CN1145494C (en) | Ebikang medicine for treating nasal disorders and its preparation method | |
CN104288623B (en) | A kind of medicinal liquor for treating waist dish outstanding | |
CN103156938B (en) | Hmong drug for treating diabetes mellitus | |
CN110742938A (en) | Cough relieving tea and preparation method thereof | |
CN1068523C (en) | Medicine for treating cancer and its preparing technology | |
CN110664931A (en) | Traditional Chinese medicine for treating cough and preparation method thereof | |
CN110934949A (en) | Traditional Chinese medicine for treating hydrocephalus and hematoma after cerebral hemorrhage and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |